Edition:
India

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

4.74EUR
6:18pm IST
Change (% chg)

€0.05 (+1.17%)
Prev Close
€4.68
Open
€4.69
Day's High
€4.79
Day's Low
€4.69
Volume
13,620
Avg. Vol
56,072
52-wk High
€5.38
52-wk Low
€3.10

Latest Key Developments (Source: Significant Developments)

Ab Science Says IDMC Recommends Continuation Of masitinib Phase 3 Study With No Requirement To Increase Sample Size
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - AB SCIENCE SA ::REG-AB SCIENCE ANNOUNCES THAT BASED ON INTERIM ANALYSIS, IDMC RECOMMENDED THE CONTINUATION OF THE MASITINIB PHASE 3 STUDY IN PROGRESSIVE MULTIPLE SCLEROSIS WITH NO REQUIREMENT TO INCREASE THE SAMPLE SIZE.‍FINAL RESULTS OF STUDY ARE EXPECTED IN Q2 2019​.‍IDMC DID NOT REPORT ANY SAFETY CONCERN WITH MASITINIB IN STUDY POPULATION​.  Full Article

AB Science net loss narrows to 13.5 million euros
Thursday, 31 Aug 2017 

Aug 31 (Reuters) - AB SCIENCE SA ::NET LOSS OF 13.5MEUR IN FIRST HALF OF 2017, A DECREASE OF 8.4% AS COMPARED WITH FIRST HALF OF 2016 (14.7MEUR ).CASH POSITION OF 49.3MEUR AS OF 30 JUNE 2017, PLUS 6.9MEUR OF 2016 TAX CREDIT TO BE REIMBURSED BY PUBLIC FINANCE DEPARTMENT.PHASE 2/3 STUDY AB10015 OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) MET ITS PRE-SPECIFIED PRIMARY ENDPOINT, WHICH CONFIRMS INTERIM ANALYSIS.COMPANY TURNOVER AMOUNTS TO 842 K€ FOR THE FIRST HALF OF 2017, AS COMPARED WITH 772 K€ ONE YEAR EARLIER.OPERATING LOSS AS AT 30 JUNE 2017 AMOUNTED TO 13,709 K€ AS COMPARED WITH 16,099 K€ AS AT 30 JUNE 2016.  Full Article

AB Science announces issuance of a new european patent
Wednesday, 12 Jul 2017 

July 12 (Reuters) - AB SCIENCE SA ::REG-AB SCIENCE ANNOUNCES ISSUANCE OF A NEW EUROPEAN PATENT FOR PROTECTING THE USE OF MASITINIB IN PANCREATIC CANCER PATIENTS.ANNOUNCES ISSUANCE OF A NEW EUROPEAN PATENT FOR PROTECTING USE OF MASITINIB IN PANCREATIC CANCER PATIENTS WITH PAIN UNTIL 2033.RECRUITMENT TARGET OF 330 PATIENTS IN ONGOING CONFIRMATORY PHASE 3 STUDY HAS JUST BEEN REACHED.  Full Article

Ab Science: CHMP adoptes negative opinion for masitinib in indolent systemic mastocytosis
Wednesday, 17 May 2017 

May 17 (Reuters) - AB SCIENCE SA ::REG-AB SCIENCE ANNOUNCES THAT CHMP HAS ADOPTED A NEGATIVE OPINION FOR MASITINIB IN INDOLENT SYSTEMIC MASTOCYTOSIS, PRIMARILY DUE TO GCP INSPECTION FINDINGS.AB SCIENCE WILL ASK FOR A RE-EXAMINATION WITH OPINION OF A SCIENTIFIC ADVISORY GROUP (SAG) TO EVALUATE BENEFIT-RISK BALANCE.HAS IMPLEMENTED THE CORRECTIVE ACTIONS TO ADDRESS THE GCP FINDINGS.AB SCIENCE WILL ASK FOR A RE-EXAMINATION.RE-EXAMINATION SHOULD LEAD THE CHMP TO DELIVER A SECOND OPINION IN Q4 2017.  Full Article

Trading resumption on shares of AB Science
Monday, 15 May 2017 

May 15 (Reuters) - Euronext::Announced today that trading on ordinary shares issued by AB Science <<>> will resume on Euronext Paris as of May 16, 2017 at 0900 CET.  Full Article

BRIEF-AB Science Presents New Preclinical Data For Masitinib In ALS

* ANNOUNCED ON TUESDAY NEW PRECLINICAL DATA FOR MASITINIB IN ALS AT 2019 MUSCULAR DYSTROPHY ASSOCIATION CONFERENCE